These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 28885719)
21. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
22. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs. Hari P; Ung B; Abouzaid S; Agarwal A; Parikh K Future Oncol; 2019 Dec; 15(35):4045-4056. PubMed ID: 31625415 [No Abstract] [Full Text] [Related]
23. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT. Syed YY Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622 [TBL] [Abstract][Full Text] [Related]
24. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448 [TBL] [Abstract][Full Text] [Related]
25. Developments in consolidation and maintenance strategies in post-remission multiple myeloma. Morè S; Corvatta L; Maracci L; Costantini B; Olivieri A; Offidani M Expert Rev Hematol; 2020 Apr; 13(4):351-362. PubMed ID: 32162982 [No Abstract] [Full Text] [Related]
26. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855 [TBL] [Abstract][Full Text] [Related]
27. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation. Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560 [TBL] [Abstract][Full Text] [Related]
28. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Nathwani N; Larsen JT; Kapoor P Curr Hematol Malig Rep; 2016 Apr; 11(2):127-36. PubMed ID: 26893062 [TBL] [Abstract][Full Text] [Related]
29. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443 [TBL] [Abstract][Full Text] [Related]
31. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; Broijl A; Croockewit A; Minnema MC; Waage A; Hveding C; van de Donk NWCJ; Offidani M; Palumbo GA; Spencer A; Boccadoro M; Cavo M J Clin Oncol; 2021 Nov; 39(32):3613-3622. PubMed ID: 34520219 [TBL] [Abstract][Full Text] [Related]
32. Role of Autologous Transplant in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Triplets: A Systematic Review and Meta-Analysis. Amitai I; Gurion R; Raanani P; Vaxman I; Yeshurun M; Magen H; Gafter-Gvili A; Shargian L Acta Haematol; 2024 Sep; ():1-9. PubMed ID: 39284295 [TBL] [Abstract][Full Text] [Related]
33. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149 [TBL] [Abstract][Full Text] [Related]
34. Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. Gay F; Jackson G; Rosiñol L; Holstein SA; Moreau P; Spada S; Davies F; Lahuerta JJ; Leleu X; Bringhen S; Evangelista A; Hulin C; Panzani U; Cairns DA; Di Raimondo F; Macro M; Liberati AM; Pawlyn C; Offidani M; Spencer A; Hájek R; Terpos E; Morgan GJ; Bladé J; Sonneveld P; San-Miguel J; McCarthy PL; Ludwig H; Boccadoro M; Mateos MV; Attal M JAMA Oncol; 2018 Oct; 4(10):1389-1397. PubMed ID: 30098165 [TBL] [Abstract][Full Text] [Related]
35. Autologous transplantation and maintenance therapy in multiple myeloma. Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862 [TBL] [Abstract][Full Text] [Related]
36. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Lahoud OB; Landau H; Nguyen J; Devlin S; Lendvai N; Weltz J; Ayorinde T; Chung DJ; Lesokhin AM; Kewalramani T; Korde N; Mailankody S; Landgren O; Giralt S; Comenzo RL; Hassoun H Leuk Lymphoma; 2022 Sep; 63(9):2126-2135. PubMed ID: 35648041 [TBL] [Abstract][Full Text] [Related]
37. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708 [TBL] [Abstract][Full Text] [Related]
38. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081 [TBL] [Abstract][Full Text] [Related]
39. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Ozaki S; Handa H; Koiso H; Saitoh T; Sunami K; Ishida T; Suzuki K; Narita T; Iida S; Nakamura Y; Suzuki K; Nishimura N; Murakami H; Shimizu K J Cancer Res Clin Oncol; 2022 Jan; 148(1):191-203. PubMed ID: 34080068 [TBL] [Abstract][Full Text] [Related]
40. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma. Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]